Google Cloud has announced two new AI-powered life sciences solutions to accelerate drug discovery and precision medicine for biotech companies, pharmaceutical firms, and public sector organizations. \n\n\n\nThe Target and Lead Identification Suite helps researchers better identify the function of amino acids and predict the structure of proteins; and the Multiomics Suite accelerates the discovery and interpretation of genomic data, helping companies design precision treatments. \n\n\n\n"We've long been involved with creating new tools for understanding and working with the code of life, like high performance computing for genomic analytics, and artificial intelligence that can predict three-dimensional models of proteins," said Shweta Maniar, global director, Life Sciences Strategy and Solutions, Google Cloud. \n\n\n\n"These new solutions launching today can transform life sciences organizations by accelerating drug discovery and bringing therapeutics to market faster. When patients are waiting for that life-saving treatment in cancer care or that quality-of-life medicine for migraine headaches, this faster time-to-market can have an incredibly positive impact on lives."\n\n\n\nAccelerating drug discovery\n\n\n\nSpeeding up target and lead identification is critical for the race to drug discovery. Currently, developing a new drug from an original idea to the launch of a finished product is a complex process that can take 12 to 15 years and cost more than $1 billion, according to the British Journal of Pharmacology. \n\n\n\nIn addition, identifying a biological target involved in the disease that is viable for drug intervention can take up to 12 months. Many companies use X-ray crystallography and nuclear magnetic resonance (NMR) to determine protein 3D structures, but this has a high ratio of failures. Finally, once the drug discovery process is under way, it's not easy to scale supporting technology up or down based on demand.\n\n\n\nGoogle Cloud's Target and Lead Identification Suite enables biopharma companies to bring therapeutics to market faster by enabling more efficient in silico drug design. Its target identification will help companies quickly predict antibody structures, assess the structure and function of amino acid mutagenesis, and accelerate de novo protein design. This solution also enables lead optimization that can be used to discover novel, high-quality candidates at low cost for Quantitative Structure Activity Relationship (QSAR) studies or for Free Energy Perturbation (FEP) calculations.\n\n\n\nThe Target and Lead Identification Suite includes: data ingestion, target identification and lead identification.\n\n\n\nEarly adopters for the Target and Lead Identification Suite include multinational pharmaceutical companies like Pfizer, and biotech companies such as Cerevel.\n\n\n\n"We are partnering with Google on exploring how AlphaFold2 can potentially accelerate our drug discovery process, speeding up our researchers' ability to conduct their experiments on Google Cloud's scalable, accelerator-optimized compute platform," said Nicholas Labello, senior principal computational scientist at Pfizer, Inc.\n\n\n\n"At Cerevel we aim to unravel the mysteries of the brain to solve some of the most difficult to treat neuroscience diseases, including evaluating novel therapies for schizophrenia, epilepsy, and Parkinson's disease. The Target and Lead Identification Suite with AlphaFold gives us a valuable tool to more efficiently evaluate and improve our discovery efforts," said Claude Barberis, vice president, medicinal chemistry at Cerevel. \n\n\n\n"The deeper understanding and insights we will be able to derive could ultimately get treatments for the most devastating neuroscience diseases onto the market faster, improving the day-to-day lives of millions of people."\n\n\n\nAbout Google Cloud's Multiomics Suite\n\n\n\nGenomic differences can affect susceptibility to certain diseases and the way that people respond to medicines, and increasing the diversity and pool of genomic understanding can help realize the potential of precision medicine. But harnessing the exponential growth in genomic data requires significant resources that many organizations are not able to support. In addition, there are high costs associated with acquiring, storing, distributing, and analyzing genomic data as the volume of data continues to increase, doubling every 7-12 months.\n\n\n\nGoogle Cloud's Multiomics Suite advances precision medicine care by transforming multiomics data into insights to advance scientific discoveries. Organizations can use this solution to streamline and accelerate analysis of genomic data, design clinical genomics, accelerate personalized medicine, and interpret genomic data to unlock new discoveries. The solution also provides structure and processes for researchers and data scientists to collaborate, saving time on developing net new paths, algorithms, or methods.\n\n\n\nWhat sets the Multiomics Suite apart is that it is cloud agnostic, allowing organizations to leverage existing investments in multiomics in a simplified environment. It also offers complete traceability through Vertex AI, so customers can organize millions of artifacts in their cloud environments. Finally, it leverages the power of Google Research to transform hundreds of thousands of files, samples, and records to load variant call format (VCF) files from Google Cloud Storage into BigQuery for analysis.\n\n\n\n"Google Cloud life science customers can benefit from our long experience in this domain. Vertex AI Pipelines and Datasets features are what provide this important, complete traceability for advanced experiments," said Maniar.\n\n\n\nThe Mutiomics Suite includes: data ingestion and analytics, secondary analysis and tertiary analysis.\n\n\n\nReduced cost and time\n\n\n\n"Combining the science of genetics with the business of discovery, we endeavor to advance the economies of biology and healing through genetics," said Alexander Titus, vice president of strategy & computational sciences at Colossal Biosciences. \n\n\n\n"With Google Cloud's Multiomics Suite, Colossal was able to see 52% reduction in overall cost and an 88% reduction in time to execute whole genome sequence analysis when compared with open-source tools — demonstrating dramatic improvements in overall computational efficiency. This accelerates our ability to solve critical problems for all life on Earth."\n\n\n\nGoogle Cloud's ecosystem of delivery partners provides expert implementation of services for Target and Lead Identification Suite and Multiomics Suite to help life sciences organizations deploy at scale. These partners include EPAM Systems, Inc., Form Bio, Max Kelsen, Omnigen, Quantiphi, and others.\n\n\n\nForm Bio said the collaboration is a natural fit, with its founding mission to help scientists drive their next breakthroughs. \n\n\n\n“Surging interest in bioinformatics and AI is inspiring a wave of life science companies to turn to cloud-based computing,” said Mark Swendsen, chief revenue officer for Form Bio. \n\n\n\n"Form Bio has a team of industry experts and is built on Google Cloud’s advanced high performance computing, data analytics, and AI technology, putting us ahead of the curve." \n\n\n\n“With Google Cloud’s powerful platform, Form Bio is positioned to increase life sciences research data accessibility, ease of use, and interpretability. Through this alliance with Google Cloud, we will be able to drive automation and optimization for the industry, empower life sciences researchers to accelerate their breakthroughs and broaden our scope and reach for the science and academic communities,” added Swendsen.